A nationwide cohort study suggests clarithromycin-based therapy for Helicobacter pylori eradication is safe in patients with stable coronary heart disease and subsequent peptic ulcer disease

• Published in: BMC gastroenterology Vol. 22; no. 1; pp. 1 - 416
• Main Authors: Chen, Yen-Chun, Li, Yi-Da, Yu, Ben-Hui, Chen, Yi-Chun
• Format: Journal Article
• Language: English
• Published: London BioMed Central Ltd 12.09.2022; BioMed Central; BMC
• Subjects: Ambulatory care; Angioplasty; Arrhythmia; Bias; Cardiovascular disease; Cardiovascular diseases; Cardiovascular morbidity; Cardiovascular mortality; Chronic obstructive pulmonary disease; Clarithromycin; Cohort analysis; Complications and side effects; Control; Coronary artery disease; Coronary heart disease; Drug dosages; Eradication; Gastroenterology; Heart; Heart diseases; Helicobacter pylori; Infections; Morbidity; Mortality; Observational studies; Overall mortality; Patient outcomes; Patients; Peptic ulcer; Peptic ulcer disease; Peptic ulcers; Pneumonia; Prevention; Risk factors; Stroke; Testing; Ulcers; Taiwan
• ISSN: 1471-230X; 1471-230X
• DOI: 10.1186/s12876-022-02498-1

Abstract Background Clarithromycin-based therapy is important for Helicobacter pylori eradication treatment. However, clarithromycin may increase cardiovascular risk. Hence, we investigated the association between clarithromycin use and outcomes in adults with stable coronary heart disease (CHD) and subsequent peptic ulcer disease (PUD). Methods This nationwide cohort study used a national health insurance database to screen 298,417 Taiwanese residents who were diagnosed with coronary heart disease from 2001 to 2015 for eligibility in the study and to evaluate select eligible patients with CHD–PUD from 2004 to 2015. Data were obtained from new users of clarithromycin (n = 4183) and nonusers of clarithromycin (n = 24,752) during follow-up. A total of 4070 eligible clarithromycin users and 4070 nonusers were subject to final analysis by 1:1 propensity score matching. Participants were followed up after receiving clarithromycin or at the corresponding date until the occurrence of cardiovascular morbidity in the presence of competing mortality, overall mortality and cardiovascular mortality, or through the end of 2015. The incidence rates and risks of overall mortality and cardiovascular outcomes were evaluated. The associations between clarithromycin and arrhythmia risk, as well as its dose and duration and overall mortality and cardiovascular outcomes were also addressed. Results Clarithromycin users were associated with adjusted hazard ratios of 1.08 (95% confidence interval, 0.93–1.24; 21.5 compared with 21.2 per 1000 patient-years) for overall mortality, 0.95 (0.57–1.59; 1.5 compared with 1.8 per 1000 patient-years) for cardiovascular mortality, and 0.94 (0.89–1.09; 19.6 compared with 20.2 per 1000 patient-years) for cardiovascular morbidity in the presence of competing mortality, as compared with nonusers. We found no relationship between dose and duration of clarithromycin and overall mortality and cardiovascular outcomes and no increased risk of arrhythmia during follow-up period. After inclusion of arrhythmia events to re-estimate the risks of all study outcomes, the results remained insignificant. Conclusion Concerning overall mortality, cardiovascular mortality, and cardiovascular morbidity, our results suggest clarithromycin-based therapy for Helicobacter pylori eradication may be safe in patients with stable CHD and subsequent PUD.